NCT02282358 2024-03-08
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT02429375 2022-05-12
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00358982 2015-07-03
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00359086 2015-07-01
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Mirati Therapeutics Inc.
Phase 2 Completed